31
Views
10
CrossRef citations to date
0
Altmetric
Research Article

Response of CD30+ Large Cell Lymphoma of Skin to Bexarotene

, &
Pages 1153-1154 | Published online: 01 Jul 2009

  • Harris, N.L., Jaffe, E.S., Stein, H. Banks, P.M. Chan, J.K. Cleary, M.L. et al. (1994) "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood 84(5), 1361-1392.
  • Grange, R, Hedelin, G., Joly, P., Beylot-Barry, M., D'incan, M. Delaunay, M. et al. (1999) "Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sezary syndrome The French Study Group on Cutaneous Lymphomas". Blood 93(11), 3637-3642.
  • Vergier, B. de Muret, A. Beykrt-Bany, M. Vaillant, L., Ekouevi, D. Chene, G., et al. (2000) 'Transformation of mycosis fungoides: clinicopathlogical and prognostic features of 45 cases French Study Group of Cutaneous Lymphomas". Blood 95(7), 2212-2218.
  • Duvic, M. Hymes, K. Heald, P. Breneman, D., Martin, A.G., Myskowski, P., et al. (2001) "Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results". J. Clin. Oncol. 19(9), 2456-2471.
  • Wu, H. Telang, G.H. Lessin, S.R. and Vonderheid, E.C. (2000) "Mycosis fungoides with CD30-positive cells in the epidermis". Am. J. Dermatopathol. 22(3). 212-216.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.